Booth#6

We're excited to be part of Biologics US 2024, taking place October 3-4 in San Diego, CA. As biologics continue to lead the pharmaceutical industry, they also present unique challenges. Join over 550 industry leaders to explore the strategies and technologies needed to bring more effective biological products to market.

The two-day event will feature case studies and programs on next-generation Protein & Antibody Therapeutics, Peptides, and Antibody-Drug Conjugates. Engage in networking opportunities to advance your pipeline from bench to bedside.

Visit us at Booth #6 to discover GenScript's latest innovations in antibody generation, protein engineering, and cGMP peptides. Connect with our experts and learn how our solutions can accelerate your research and clinical applications. We look forward to seeing you there!

Presentation

Next-Gen Antibody Engineering for GPCRs by integrating Autonomous Yeast Display and AI

Date & Time: 10/4 10:35-10:55 am PT

Speaker: Alon Wellner, PhD. VP of Biology, Aureka Biotechnologies

Bio: Alon Wellner is the Vice President of Biology at Aureka Biotechnologies, leading a team to develop a cutting-edge therapeutic discovery pipeline using high-throughput biology and AI. He completed postdoctoral training at UC Irvine and holds a Ph.D. in Biochemistry from the Weizmann Institute of Science. With extensive experience in protein and antibody engineering, Alon has held multiple leadership roles, managing multinational research teams and pioneering novel drug discovery platforms.

Read More >>

Abstract:
Traditional antibody generation is often slow and costly. AuraQuest™ utilizes yeast surface display and autonomous hypermutation to mimic animal immunization, enabling rapid antibody discovery. Combined with the AI platform AuraPicasso™, this approach accelerates the engineering of antibodies with specific characteristics. This method has effectively targeted challenging antigens like GPCRs, demonstrating potent nanobody isolation within two weeks through affinity maturation using yeast culturing and FACS.